Abstract
Therapy options for patients with recurrent, platinum-resistant ovarian cancer are limited. Cortisol contributes to chemotherapy resistance, one driver of poor outcomes, by suppressing apoptotic pathways used by cytotoxic agents. A phase 2 study of relacorilant (RELA) + nab-paclitaxel (NP) in patients with ovarian cancer has shown that glucocorticoid receptor modulation with RELA can improve the efficacy of NP. In all patients, intermittent RELA + NP significantly improved progression-free survival (PFS) and improved overall survival (OS) without additional side-effect burden.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
